J 2017

Panitumumab use in metastatic colorectal cancer and patterns of RAS testing: results from a Europe-wide physician survey and medical records review

KRIEKEN, Han J. van, G. KAFATOS, J. BENNETT, L. MINEUR, Jiří TOMÁŠEK et. al.

Basic information

Original name

Panitumumab use in metastatic colorectal cancer and patterns of RAS testing: results from a Europe-wide physician survey and medical records review

Authors

KRIEKEN, Han J. van (528 Netherlands), G. KAFATOS (826 United Kingdom of Great Britain and Northern Ireland), J. BENNETT (826 United Kingdom of Great Britain and Northern Ireland), L. MINEUR (250 France), Jiří TOMÁŠEK (203 Czech Republic, guarantor, belonging to the institution), E. ROULEAU (250 France), Pavel FABIAN (203 Czech Republic, belonging to the institution), G. DE MAGLIO (380 Italy), P. GARCIA-ALFONSO (724 Spain), G. APRILE (380 Italy), P. PARKAR (826 United Kingdom of Great Britain and Northern Ireland), G. DOWNEY (826 United Kingdom of Great Britain and Northern Ireland), G. DEMONTY (756 Switzerland) and J. TROJAN (276 Germany)

Edition

BMC Cancer, London, BioMed Central, 2017, 1471-2407

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 3.288

RIV identification code

RIV/00216224:14110/17:00099927

Organization unit

Faculty of Medicine

DOI

UT WoS

000416427500005

Keywords in English

Panitumumab; Metastatic colorectal cancer; mCRC; RAS; Physician survey; Medical records review

Tags

Tags

International impact, Reviewed
Změněno: 20/3/2018 19:09, Soňa Böhmová

Abstract

V originále

Background: In Europe, treatment of metastatic colorectal cancer (mCRC) with panitumumab requires prior confirmation of RAS wild-type mutation status. Two studies - a physician survey and a medical records review (MRR) - were conducted to evaluate the use of panitumumab and awareness among prescribing oncologists of the associated RAS testing requirements in clinical practice. Methods: Both studies enrolled participants from nine European countries and were carried out in three consecutive rounds. Rounds 1 and 2 (2012-2013) examined KRAS (exon 2) testing only; the results have been published in full previously. Round 3 (2014-2015) examined full RAS testing (exons 2, 3, 4 of KRAS and NRAS) and was initiated following a change in prescribing guidelines, from requiring KRAS alone to requiring full RAS testing. For the physician survey, telephone interviews were conducted with oncologists who had prescribed panitumumab to patients with mCRC in the previous 6 months. For the MRR, oncologists were asked to provide anonymised clinical information, extracted from their patients' records. Results: In Round 3, 152 oncologists and 131 patients' records were included in the physician survey and MRR, respectively. In Round 3 of the physician survey, 95.4% (n = 145) of participants correctly identified that panitumumab should only be prescribed in RAS wild-type mCRC compared with 99.0% (n = 298) of 301 participants in Rounds 1 and 2, responding to the same question about KRAS testing. In Round 3 of the MRR, 100% (n = 131) of patients included in the study had confirmed KRAS or RAS wild-type status prior to initiation of panitumumab compared with 97.7% (n = 299) of 306 patients in Rounds 1 and 2 (KRAS only). Of those patients in Round 3, 83.2% (n = 109) had been tested for RAS status and 16.8% (n = 22) had been tested for KRAS status only. Conclusions: Physicians' adherence to prescribing guidelines has remained high over time in Europe, despite the change in indication for panitumumab treatment, from KRAS to RAS wild-type mCRC. Additionally, this study demonstrates the uptake of full RAS testing among the majority of oncologists and pathologists.